This is the first vaccine against the illness that has been given this recognition by a country. It is approved for use against all serotypes of the virus in individuals between nine and 45 years old.
The vaccine, known as Dengvaxia, is currently under review in other areas of the world where this disease common, specifically countries located in tropical and subtropical regions.
"Today, with this first marketing authorization of Dengvaxia, we have achieved our goal of making dengue the next vaccine-preventable disease,” Sanofi CEO Dr. Oliver Brandicourt said. “This is a historic milestone for our company, for the global public health community and, most importantly, for half the world's population who lives at risk of dengue."
The Federal Commission for the Protection against Sanitary Risks approved the vaccine based on its performance in clinical trials among various age groups and epidemiological environments.
The World Health Organization (WHO) reports that dengue fever is among the fastest mosquito-borne illnesses in terms of growth. Approximately 400 million people are affected on average every year.
Sanofi Pasteur, the vaccines division of Sanofi, is a global company that provides more than one billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe.